Liposome-encapsulated midazolam for oral administration

Yumiko Tomoyasu, Tatsuji Yasuda, Shigeru Maeda, Hitoshi Higuchi, Takuya Miyawaki

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The oral administration of midazolam has often been used for sedation in pediatric patients. However, oral administration of an intravenous formulation of midazolam is difficult for younger pediatric patients because of its bitter taste. Liposomes have been developed as vesicles encapsulating various kinds of drugs to serve as a medical drug-delivery system. Thus, the aim of the present study was to produce pH-sensitive liposomes encapsulating midazolam and to evaluate its pharmacokinetics on rabbits. Liposome-encapsulated midazolam was produced from hydrogenated L-α-phosphatidylcholine, cholesterol, dipalmitoylphosphatidic acid, and midazolam. The capacity of liposomes to encapsulate midazolam (encapsulation efficiency), stability of encapsulation, and release efficiency were evaluated in vitro. Further, the produced liposome-encapsulated midazolam solution was orally administered to rabbits in vivo. As a result, midazolam was encapsulated by liposomes with a high encapsulation efficiency and was stably encapsulated in a physiological medium. Further, the produced liposomes rapidly and effectively released midazolam in an acidic medium in vitro. When the liposome-encapsulated midazolam solution was orally administered to rabbits, the time to achieve the maximum plasma concentration of midazolam after administration was slightly longer, but both the maximum plasma concentration and area under the concentration-time curve were higher than those receiving midazolam solution. In conclusion, we produced pH-sensitive liposome-encapsulated midazolam, which remained stable in a physiological medium and showed efficient release in an acidic environment. The results suggest that it is possible to clinically use liposome-encapsulated midazolam for oral administration as a useful drug-delivery vehicle.

Original languageEnglish
Pages (from-to)166-172
Number of pages7
JournalJournal of Liposome Research
Volume21
Issue number2
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Midazolam
Liposomes
Oral Administration
Rabbits
Pediatrics
Drug Delivery Systems
Phosphatidylcholines
Pharmaceutical Preparations

Keywords

  • delivery vehicle
  • Liposome
  • midazolam
  • oral administration
  • pharmacokinetics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Liposome-encapsulated midazolam for oral administration. / Tomoyasu, Yumiko; Yasuda, Tatsuji; Maeda, Shigeru; Higuchi, Hitoshi; Miyawaki, Takuya.

In: Journal of Liposome Research, Vol. 21, No. 2, 06.2011, p. 166-172.

Research output: Contribution to journalArticle

@article{7689975aa5de4b2691f42e4fb20de8ba,
title = "Liposome-encapsulated midazolam for oral administration",
abstract = "The oral administration of midazolam has often been used for sedation in pediatric patients. However, oral administration of an intravenous formulation of midazolam is difficult for younger pediatric patients because of its bitter taste. Liposomes have been developed as vesicles encapsulating various kinds of drugs to serve as a medical drug-delivery system. Thus, the aim of the present study was to produce pH-sensitive liposomes encapsulating midazolam and to evaluate its pharmacokinetics on rabbits. Liposome-encapsulated midazolam was produced from hydrogenated L-α-phosphatidylcholine, cholesterol, dipalmitoylphosphatidic acid, and midazolam. The capacity of liposomes to encapsulate midazolam (encapsulation efficiency), stability of encapsulation, and release efficiency were evaluated in vitro. Further, the produced liposome-encapsulated midazolam solution was orally administered to rabbits in vivo. As a result, midazolam was encapsulated by liposomes with a high encapsulation efficiency and was stably encapsulated in a physiological medium. Further, the produced liposomes rapidly and effectively released midazolam in an acidic medium in vitro. When the liposome-encapsulated midazolam solution was orally administered to rabbits, the time to achieve the maximum plasma concentration of midazolam after administration was slightly longer, but both the maximum plasma concentration and area under the concentration-time curve were higher than those receiving midazolam solution. In conclusion, we produced pH-sensitive liposome-encapsulated midazolam, which remained stable in a physiological medium and showed efficient release in an acidic environment. The results suggest that it is possible to clinically use liposome-encapsulated midazolam for oral administration as a useful drug-delivery vehicle.",
keywords = "delivery vehicle, Liposome, midazolam, oral administration, pharmacokinetics",
author = "Yumiko Tomoyasu and Tatsuji Yasuda and Shigeru Maeda and Hitoshi Higuchi and Takuya Miyawaki",
year = "2011",
month = "6",
doi = "10.3109/08982104.2010.498002",
language = "English",
volume = "21",
pages = "166--172",
journal = "Journal of Liposome Research",
issn = "0898-2104",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Liposome-encapsulated midazolam for oral administration

AU - Tomoyasu, Yumiko

AU - Yasuda, Tatsuji

AU - Maeda, Shigeru

AU - Higuchi, Hitoshi

AU - Miyawaki, Takuya

PY - 2011/6

Y1 - 2011/6

N2 - The oral administration of midazolam has often been used for sedation in pediatric patients. However, oral administration of an intravenous formulation of midazolam is difficult for younger pediatric patients because of its bitter taste. Liposomes have been developed as vesicles encapsulating various kinds of drugs to serve as a medical drug-delivery system. Thus, the aim of the present study was to produce pH-sensitive liposomes encapsulating midazolam and to evaluate its pharmacokinetics on rabbits. Liposome-encapsulated midazolam was produced from hydrogenated L-α-phosphatidylcholine, cholesterol, dipalmitoylphosphatidic acid, and midazolam. The capacity of liposomes to encapsulate midazolam (encapsulation efficiency), stability of encapsulation, and release efficiency were evaluated in vitro. Further, the produced liposome-encapsulated midazolam solution was orally administered to rabbits in vivo. As a result, midazolam was encapsulated by liposomes with a high encapsulation efficiency and was stably encapsulated in a physiological medium. Further, the produced liposomes rapidly and effectively released midazolam in an acidic medium in vitro. When the liposome-encapsulated midazolam solution was orally administered to rabbits, the time to achieve the maximum plasma concentration of midazolam after administration was slightly longer, but both the maximum plasma concentration and area under the concentration-time curve were higher than those receiving midazolam solution. In conclusion, we produced pH-sensitive liposome-encapsulated midazolam, which remained stable in a physiological medium and showed efficient release in an acidic environment. The results suggest that it is possible to clinically use liposome-encapsulated midazolam for oral administration as a useful drug-delivery vehicle.

AB - The oral administration of midazolam has often been used for sedation in pediatric patients. However, oral administration of an intravenous formulation of midazolam is difficult for younger pediatric patients because of its bitter taste. Liposomes have been developed as vesicles encapsulating various kinds of drugs to serve as a medical drug-delivery system. Thus, the aim of the present study was to produce pH-sensitive liposomes encapsulating midazolam and to evaluate its pharmacokinetics on rabbits. Liposome-encapsulated midazolam was produced from hydrogenated L-α-phosphatidylcholine, cholesterol, dipalmitoylphosphatidic acid, and midazolam. The capacity of liposomes to encapsulate midazolam (encapsulation efficiency), stability of encapsulation, and release efficiency were evaluated in vitro. Further, the produced liposome-encapsulated midazolam solution was orally administered to rabbits in vivo. As a result, midazolam was encapsulated by liposomes with a high encapsulation efficiency and was stably encapsulated in a physiological medium. Further, the produced liposomes rapidly and effectively released midazolam in an acidic medium in vitro. When the liposome-encapsulated midazolam solution was orally administered to rabbits, the time to achieve the maximum plasma concentration of midazolam after administration was slightly longer, but both the maximum plasma concentration and area under the concentration-time curve were higher than those receiving midazolam solution. In conclusion, we produced pH-sensitive liposome-encapsulated midazolam, which remained stable in a physiological medium and showed efficient release in an acidic environment. The results suggest that it is possible to clinically use liposome-encapsulated midazolam for oral administration as a useful drug-delivery vehicle.

KW - delivery vehicle

KW - Liposome

KW - midazolam

KW - oral administration

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=79956132193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79956132193&partnerID=8YFLogxK

U2 - 10.3109/08982104.2010.498002

DO - 10.3109/08982104.2010.498002

M3 - Article

C2 - 20684674

AN - SCOPUS:79956132193

VL - 21

SP - 166

EP - 172

JO - Journal of Liposome Research

JF - Journal of Liposome Research

SN - 0898-2104

IS - 2

ER -